Zenyth Therapeutics Limited

Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas of inflammation and cancer. Zenyth has intellectual property rights to a number of key molecules which have pivotal roles in cancer and inflammatory diseases including rheumatoid arthritis and asthma. Zenyth’s scientific team has expertise in antibody generation and engineering and works closely with academic medical research institutes as well as local and international pharmaceutical and biotechnology companies to advance therapies from the discovery phase through to commercialisation. Zenyth’s current corporate partners include Merck and Co., Inc., Cambridge Antibody Technology, MuriGen Therapeutics and Medarex Inc. In addition, Zenyth has an antibody library licence agreement with Dyax Corporation.

Contact Details: ABN 37 006 614 375576 Swan Street Richmond Victoria 3121 Australia Tel: 61 3 9208 4000 Fax: 61 3 9208 4350 Email: WWW: www.amrad.com.au/

Press Releases on Zenyth Therapeutics Limited:
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL	27th October, 2008		MELBOURNE, Australia, October 27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other

BioNews Results for Zenyth Therapeutics Limited:
Ark Therapeutics Group plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new	PR inside:  Nov 16 2009 5:01AM Matching: therapeutics
Astex Announces Strategic Drug Discovery Alliance with GlaxoSmithKline	PipelineReview:  Nov 15 2009 8:48PM Matching: therapeutics
EKR Therapeutics to Present at the Lazard Capital Markets 2009 Healthcare Conference	Pharma Live:  Nov 14 2009 10:40PM Matching: therapeutics
Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002	KOTA Territory News:  Nov 14 2009 11:05PM Matching: therapeutics
Esperion Therapeutics Initiates Phase I Clinical Study For ETC-1002	Medical News Today:  Nov 14 2009 10:16AM Matching: therapeutics
Promote your company here: BioNewsCast - Press Release Distribution	→View more Zenyth Therapeutics Limited news.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 586 times since April 2007, the link to the organisation's website has been followed 99 times

Recent Search Terms used to find this page: merk zenyth deal | zenyth therapeutics | zenyth therapeutics | Merck Co and Zenyth Therapeutics | zenyth richmond | zenyth richmond | drugs developed by zenyth | Zenyth | Zenyth Therapeutics Limited | Zenyth Therapeutics | .

Search for more companies in Richmond

Search for more companies in Victoria

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Zenyth Therapeutics Limited